Exploration of Drug Science

From: Prediction of absolute bioavailability of medicines in adults and children from oral clearance

Table 2. Within fold-error and statistical analysis for the prediction of absolute bioavailability in adults (medicines metabolized in the liver and the gut) (n = 20).

Fold-error and statistical analysis
Fold-error	LBF	LPF
0.5–2	20 (100.0%)	20 (100.0%)
0.5–1.5	15 (75.0%)	20 (100.0%)
0.7–1.3	9 (45.0%)	15 (75.0%)
> 2	0 (0.0%)	0 (0.0%)
< 0.5	0 (0.0%)	0 (0.0%)
Bias	9.7	–1.2
RMSE	14.7	11.9
AFE	1.30	0.91
AAFE	1.33	1.26

Return to article view

LBF: liver blood flow; LPF: liver plasma flow; AFE: average fold error; AAFE: absolute AFE; RMSE: root mean square error. % is of total observations.

Supplementary materials

The supplementary tables for this article are available at: https://www.explorationpub.com/uploads/Article/file/1008160_sup_1.pdf.

Declarations

Author contributions

IM: Conceptualization, Investigation, Data curation, Visualization, Formal analysis, Writing—original draft, Writing—review & editing. The author read and approved the submitted version.

Conflicts of interest

The author has no conflicts of interest.

Ethical approval

Since this study analyzed secondary data, ethical approval is not required.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

The data and the references are provided in the main text and supplementary files.

Funding

No funding was received from any source.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Shargel L, Yu A. Bioavailability and bioequivalence. In: Applied Biopharmaceutics and Pharmacokinetics (3rd edition). 1993. p. 193.

Gibaldi M, Boyes R, Feldman S. Influence of first pass effect on availability of drugs on oral administration. J Pharm Sci. 1971;60:1338–40. [DOI]

Perrier D, Gibaldi M, Boyes R. Prediction of systemic availability from plasma level data after oral administration. J Pharm Pharmacol. 1973;125:256–57. [DOI]

Nicolas JM, Bouzom F, Hugues C, Ungell AL. Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions. Biopharm Drug Dispos. 2017;38:209–30. [DOI] [PubMed] [PMC]

Mahmood I. Prediction of absolute bioavailability of medicines in children: Based on predicted pediatric clearance from adults. Explor Drug Sci. 2024;2:677–87. [DOI]

Björkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol. 2005;59:691–704. [DOI] [PubMed] [PMC]

Fang X, Ding X, Zhang QY. An update on the role of intestinal cytochrome P450 enzymes in drug disposition. Acta Pharmaceutica Sinica B. 2016;6:374–83. [DOI]

Obach R, Baxter J, Liston T, Michael Silber B, Jones B, Macintyre F, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism. J Pharmacol Exp Therap. 1997;283:46–58. [DOI]

Mahmood I. A comparison of different methods for the first-in-pediatric dose selection. J Clin Transl Res. 2022;8:369–81. [PubMed] [PMC]

10.

Mahmood I. Prediction of drug clearance in children: a review of different methodologies. Expert Opin Drug Metab Toxicol. 2015;11:573–87. [DOI] [PubMed]

11.

Mahmood I. Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings. Clin Pharmacokinet. 2014;53:327–46. [DOI] [PubMed]